Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
An examination of the causes of traumatic brain injury, the mechanisms of primary and secondary injury, and how those injuries are evaluated and classified.
Physicians should fully understand the ethical principles and professional standards involved in making decisions for the treatment of impaired newborns.
Two physicians give an overview of the iPledge program and discuss the problematic aspects of the program for physicians who prescribe isotretinoin and their patients.
Drivers, physicians, and motor vehicle agencies all have some responsibility in reducing the number of fatal traffic accidents caused by driver sleepiness.